<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Fentanyl</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00813</strong>&#160; (APRD00347, DB05853)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, illicit, investigational</td></tr><tr><th>Description</th><td><p>A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078)</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00813/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00813/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00813.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00813.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00813.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00813.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00813.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00813">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Fentanil </td><td><span class="wishart wishart-not-available">Not Available</span></td><td>DCIT</td></tr><tr><td>Fentanilo</td><td>Spanish</td><td>INN</td></tr><tr><td>Fentanyl</td><td>German </td><td>INN</td></tr><tr><td>Fentanyl</td><td>French </td><td>INN</td></tr><tr><td>Fentanylum</td><td>Latin</td><td>INN</td></tr><tr><td>Phentanyl</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Fentanyl citrate</strong>
          <div class="cas">990-73-8</div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000301/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000301/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: IVLVTNPOHDFFCJ-UHFFFAOYSA-N</li>
              <li>Monoisotopic Mass: 528.247166138</li>
              <li>Average Mass: 528.594</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000301">DBSALT000301</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Abstral</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Actiq</td><td>Cephalon</td></tr><tr><td>Duragesic</td><td>Janssen</td></tr><tr><td>Durogesic</td><td>Janssen</td></tr><tr><td>Fentanest</td><td>Pfizer</td></tr><tr><td>Lazanda</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Nasalfent</td><td>Archimedes</td></tr><tr><td>Rapinyl</td><td>Gedeon Richter</td></tr><tr><td>Subsys </td><td>Insys Therapeutics </td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Innovar Injection</td><td>droperidol + fentanyl citrate</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anesthetics-intravenous">Anesthetics, Intravenous</a></li>
<li><a href="/mesh/analgesics-opioid">Analgesics, Opioid</a></li>
<li><a href="/mesh/narcotics">Narcotics</a></li>
<li><a href="/mesh/adjuvants-anesthesia">Adjuvants, Anesthesia</a></li>
<li><a href="/mesh/adjuvants">Adjuvants</a></li></ul></td></tr><tr><th>CAS number</th><td>437-38-7</td></tr><tr><th>Weight</th><td>Average: 336.4705<br>Monoisotopic: 336.220163528</td></tr><tr><th>Chemical Formula</th><td>C<sub>22</sub>H<sub>28</sub>N<sub>2</sub>O</td></tr><tr><th>InChI Key</th><td>PJMPHNIQZUBGLI-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C22H28N2O/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19/h3-12,21H,2,13-18H2,1H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Piperidines</td></tr><tr><th>Subclass</th><td>Fentanyls</td></tr><tr><th>Direct parent</th><td>Fentanyls</td></tr><tr><th>Alternative parents</th><td>Anilides; Phenethylamines; Aminopiperidines; Tertiary Carboxylic Acid Amides; Tertiary Amines; Carboxylic Acids; Enolates; Polyamines</td></tr><tr><th>Substituents</th><td>acetanilide; phenethylamine; 4-aminopiperidine; benzene; tertiary carboxylic acid amide; carboxamide group; tertiary amine; polyamine; enolate; carboxylic acid derivative; carboxylic acid; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the fentanyls. These are compounds containing the fentanyl moiety or a derivative, which is based on a N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylpropanamide skeleton.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of cancer patients with severe pain that breaks through their regular narcotic therapy.</td></tr><tr><th>Pharmacodynamics</th><td>Fentanyl is an opioid analgesic. Fentanyl interacts predominately with the opioid mu-receptor but also binds to kappa and delta-type opioid receptors. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissues. In clinical settings, Fentanyl exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation. Fentanyl may increase the patient's tolerance for pain and decrease the perception of suffering, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Fentanyl depresses the respiratory centers, depresses the cough reflex, and constricts the pupils.</td></tr><tr><th>Mechanism of action</th><td>Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Fentanyl's analgesic activity is, most likely, due to its conversion to morphine. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hypopolarization and reduced neuronal excitability.</td></tr><tr><th>Absorption</th><td>Bioavailability is 92% following transdermal administration and 50% following buccal administration.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>3 to 8 L/kg [Surgical Patients]</li>
	<li>0.8 to 8  [Hepatically Impaired Patients]</li>
</ul></td></tr><tr><th>Protein binding</th><td>80-85%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Fentanyl is metabolized primarily via human cytochrome P450 3A4 isoenzyme system.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Fentanyl</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00341">norfentanyl</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/343">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Fentanyl is metabolized primarily via human cytochrome P450 3A4 isoenzyme system and mostly eliminated in urine. Within 72 hours of IV fentanyl administration, approximately 75% of the dose is excreted in urine, mostly as metabolites with less than 10% representing unchanged drug.</td></tr><tr><th>Half life</th><td>7  hours (range 3-12)</td></tr><tr><th>Clearance</th><td><ul>
	<li>27 &#8211; 75 L/h [Surgical Patients receving IV administration]</li>
	<li>3 &#8211; 80 L/h [Hepatically Impaired Patients receving IV administration]</li>
	<li>30 &#8211; 78 L/h [Renally Impaired Patients receving IV administration]</li>
</ul></td></tr><tr><th>Toxicity</th><td>Fentanyl has an LD50 of 3.1 milligrams per kilogram in rats, and, 0.03 milligrams per kilogram in monkeys. The LD50 in humans is not known.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Fentanyl Action Pathway</td><td>Drug action</td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9766</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9901</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.6459</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.6082</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.7161</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8371</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.5824</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7879</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9117</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5856</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7715</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.873</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6327</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5724</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8218</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.7346</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8417
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8536
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.8554
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.9836 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.796
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.6791
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Ortho mcneil janssen pharmaceuticals inc</li>
<li>Actavis southatlantic llc</li>
<li>Lavipharm laboratories inc</li>
<li>Mylan technologies inc</li>
<li>Noven pharmaceuticals inc</li>
<li>Teva pharmaceuticals usa</li>
<li>Watson laboratories inc</li>
<li>Meda pharmaceuticals inc</li>
<li>Abbott laboratories hosp products div</li>
<li>Hospira inc</li>
<li>Baxter healthcare corp anesthesia and critical care</li>
<li>Marsam pharmaceuticals llc</li>
<li>Akorn inc</li>
<li>Cephalon inc</li>
<li>Barr laboratories inc</li>
<li>Mallinckrodt inc</li>
<li>Incline therapeutics inc</li>
<li>Abbott Laboratories</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.4udr.com">4uOrtho LLC</a></li>
<li><a href="http://www.actavis.com">Actavis Group</a></li>
<li><a href="http://www.akorn.com">Akorn Inc.</a></li>
<li>Alza Corp.</li>
<li>Anesta Corp.</li>
<li><a href="http://www.apotex.com">Apotex Inc.</a></li>
<li><a href="http://www.avevadds.com">Aveva Drug Delivery Systems Inc.</a></li>
<li><a href="http://www.bandbpharmaceuticals.com">B&amp;B Pharmaceuticals</a></li>
<li>Barr Pharmaceuticals</li>
<li><a href="http://www.baxter.com">Baxter International Inc.</a></li>
<li><a href="http://www.cephalon.com">Cephalon Inc.</a></li>
<li><a href="http://www.chattem.com">Chattem Chemicals Inc.</a></li>
<li><a href="http://www.cimalabs.com">Cima Laboratories Inc.</a></li>
<li><a href="http://www.coriumgroup.com">Corium International Inc.</a></li>
<li><a href="http://www.davapharma.com">DAVA Pharmaceuticals</a></li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.hospira.com">Hospira Inc.</a></li>
<li><a href="http://www.janssen-ortho.com">Janssen-Ortho Inc.</a></li>
<li><a href="http://www.ltslohmann.com">LTS Lohmann Therapy Systems Corp.</a></li>
<li><a href="http://www.mallinckrodt.com">Mallinckrodt Inc.</a></li>
<li><a href="http://www.meda.se">Meda AB</a></li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.ortho-mcneil.com">Ortho Mcneil Janssen Pharmaceutical Inc.</a></li>
<li>Pharmakon</li>
<li><a href="http://www.pharmedium.com">Pharmedium</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li>Quality Care</li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://statrxusa.exporterus.com">Stat Rx Usa</a></li>
<li>Taylor Pharmaceuticals</li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.watson.com">Watson Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Injection, solution</td><td>Intravenous</td><td>0.05 mg/mL </td></tr><tr><td>Lozenge</td><td>Oral</td><td>200 mcg; 400 mcg; 600 mcg; 800 mcg; 1200 mcg; 1600 mcg </td></tr><tr><td>Patch</td><td>Transdermal</td><td></td></tr><tr><td>Solution</td><td>Nasal</td><td>400 mcg/spray</td></tr><tr><td>Spray</td><td>Sublingual</td><td>100 mcg; 200 mcg; 400 mcg; 600 mcg; 800 mcg </td></tr><tr><td>Tablet</td><td>Buccal</td><td>100 mcg; 200 mcg; 400 mcg; 600 mcg; 800 mcg</td></tr><tr><td>Tablet</td><td>Sublingual</td><td>100 mcg; 200 mcg; 300 mcg; 400 mcg; 600 mcg; 800 mcg </td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB06274">Alvimopan</a></td><td>Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. </td></tr><tr><td><a href="/drugs/DB01118">Amiodarone</a></td><td>Possible bradycardia, hypotension</td></tr><tr><td><a href="/drugs/DB00701">Amprenavir</a></td><td>The protease inhibitor, amprenavir, may increase the effect and toxicity of fentanyl.</td></tr><tr><td><a href="/drugs/DB01128">Bicalutamide</a></td><td>CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of fentanyl. The risk of prolonged adverse effects, including potentially fatal respiratory depression is increased. Consider therapy modification.</td></tr><tr><td><a href="/drugs/DB00501">Cimetidine</a></td><td>Cimetidine, a moderate CYP3A4 inhibitor, may decrease the metabolism of fentanyl. Closely monitor changes in the therapeutic and adverse effects of fentanyl if cimetidine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00257">Clotrimazole</a></td><td>CYP3A4 Inhibitors (Moderate) such as clotrimazole may increase the serum concentration of fentanyl. Concurrent use of fentanyl with any CYP3A4 inhibitor may result in increased fentanyl concentrations and could increase or prolong adverse effects, including potentially fatal respiratory depression. Patients receiving fentanyl and any CYP3A4 inhibitor should be closely monitored for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate. </td></tr><tr><td><a href="/drugs/DB00872">Conivaptan</a></td><td>CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fentanyl. Concurrent use of fentanyl with any CYP3A4 inhibitor may result in increased fentanyl concentrations and could increase or prolong adverse effects, including potentially fatal respiratory depression. Patients receiving fentanyl and any CYP3A4 inhibitor should be closely monitored for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate. </td></tr><tr><td><a href="/drugs/DB06210">Eltrombopag</a></td><td>Increases levels of Fentanyl via metabolism decrease. UDP-glucuronosyltransferase inhibition. </td></tr><tr><td><a href="/drugs/DB00196">Fluconazole</a></td><td>Fluconazole may increase levels/toxicity of fentanyl.</td></tr><tr><td><a href="/drugs/DB01319">Fosamprenavir</a></td><td>The protease inhibitor, fosamprenavir, may increase the effect and toxicity of fentanyl.</td></tr><tr><td><a href="/drugs/DB00224">Indinavir</a></td><td>The protease inhibitor, indinavir, may increase the effect and toxicity of fentanyl.</td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>Itraconazole may increase levels/toxicity of fentanyl.</td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Ketoconazole may increase levels/toxicity of fentanyl.</td></tr><tr><td><a href="/drugs/DB00220">Nelfinavir</a></td><td>The protease inhibitor, nelfinavir, may increase the effect and toxicity of fentanyl.</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Rifampin may decrease the serum level and therapeutic effect of fentanyl.</td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>Ritonavir increases the effect and toxicity of fentanyl/alfentanyl</td></tr><tr><td><a href="/drugs/DB05271">Rotigotine</a></td><td>Pharmacodynamic synergism may increase the effects of rotigotine. Monitor therapy closely. </td></tr><tr><td><a href="/drugs/DB01232">Saquinavir</a></td><td>The protease inhibitor, saquinavir, may increase the effect and toxicity of fentanyl.</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may reduce clearance of Fentanyl. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Fentanyl if Telithromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00752">Tranylcypromine</a></td><td>Possible increased risk of serotonin syndrome. </td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>The CNS depressants, Triprolidine and Fentanyl, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of fentanyl by decreasing its metabolism. Adverse effects include life-threatening respiratory depression. Monitor for changes in the therapeutic and adverse effects of fentanyl if voriconazole is initiated, discontinued or dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li></ul></td></tr></tbody></table>